Yeji

$ASND

Ascendis Pharma A/S

NasdaqMarket cap: —CIK 0001612042

Upcoming catalysts

0 surfaced

No catalysts surfaced for ASND yet.

Drug pipeline

yuviwel
yorvipath
skytrofa
Palopegteriparatide
Hypoparathyroidism
TransCon IL-2 β/γ
Advanced Solid Tumor
TransCon TLR7/8 Agonist
Head and Neck Neoplasms
Lonapegsomatropin
Turner Syndrome
Lonapegsomatropin [SKYTROFA®]
Turner Syndrome
No intervention
Growth Hormone Deficiency
Navepegritide
Achondroplasia
TransCon CNP
Achondroplasia
TransCon Treprostinil
Healthy Volunteers
ACP-001 (TransCon hGH)
Adult Growth Hormone Deficiency
Once weekly subcutaneous injection of TransCon hGH
Growth Hormone Deficiency, Pediatric
TransCon hGH
Growth Hormone Deficiency, Pediatric
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections
Achondroplasia
TransCon PTH
Hypoparathyroidism
Palopegteriparatide Experimental Arm
Hypoparathyroidism
Palopegteriparatide (TransCon PTH)
Hypoparathyroidism
ACP-001
Growth Hormone Deficiency (GHD)
ACP-001 (TransCon PEG hGH)
Healthy

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT05929807TransCon CNPPhase 3Enrolling By Invitation2039-01-01
NCT07345494Palopegteriparatide—Recruiting2036-01-01
NCT05820672No intervention—Recruiting2033-03-01
NCT05775523No intervention—Recruiting2033-03-01
NCT07221851Lonapegsomatropin [SKYTROFA®]Phase 3Recruiting2028-02-01
NCT07264634Palopegteriparatide—Recruiting2028-01-01
NCT06079398NavepegritidePhase 2Recruiting2027-12-01
NCT05081609TransCon IL-2 β/γPhase 2Active Not Recruiting2027-08-01
NCT06732895NavepegritidePhase 2Recruiting2027-08-01
NCT07081997Palopegteriparatide Experimental ArmPhase 3Recruiting2027-06-01
NCT04799054TransCon TLR7/8 AgonistPhase 2Terminated2025-12-02
NCT06433557Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injectionsPhase 2Active Not Recruiting2025-11-14
NCT05980598TransCon TLR7/8 AgonistPhase 2Terminated2025-03-28
NCT05171855LonapegsomatropinPhase 3Completed2024-12-23
NCT05690386LonapegsomatropinPhase 2Active Not Recruiting2024-10-18
NCT05598320TransCon CNPPhase 3Completed2024-08-09
NCT03875534——Completed2024-01-12
NCT04615273LonapegsomatropinPhase 3Completed2023-11-02
NCT05246033TransCon CNPPhase 2Unknown2023-03-15
NCT03344458TransCon hGHPhase 3Completed2023-02-21

Recent catalysts

FDA approvalFeb 27, 2026· 99d ago· success
$ASNDAscendis Pharma A/S
yuviwel
“openFDA ORIG (TYPE 1) approval of YUVIWEL — application NDA219164”
FDA approvalJul 25, 2025· 316d ago· success
$ASNDAscendis Pharma A/S
skytrofa
“openFDA SUPPL (EFFICACY) approval of SKYTROFA — application BLA761177”
FDA approvalAug 9, 2024· 666d ago· success
$ASNDAscendis Pharma A/S
yorvipath
“openFDA ORIG (TYPE 1) approval of YORVIPATH — application NDA216490”
FDA approvalAug 25, 2021· 1746d ago· success
$ASNDAscendis Pharma A/S
skytrofa
“openFDA ORIG (TYPE 1) approval of SKYTROFA — application BLA761177”